Fiat Chrysler and Peugeot owner PSA Group recently announced the terms of a $48 billion merger that would create the world's fourth-largest automaker. A primary reason for the merger is to share the cost of developing electric and autonomous vehicles.

The next big technology shakeup is on its way. With a limited rollout in 2018 leading to a much more comprehensive release in 2020, 5G is here, with increased speeds, instantaneous communication, and the ability to connect just about everything.

In an update to our 2016, 2017, and 2018 lists of most difficult examiners at the USPTO, we have identified the 10 patent examiners (excluding SPEs) with the most skeptical eye toward the patent applications that cross their desks.

Pfizer and Mylan, the maker of EpiPens, are merging. Pfizer will offload Upjohn, its portfolio of drugs that are no longer protected by patents, including Viagra, Lipitor and Celebrex, combining with rival Mylan to create a new company that will have a new, yet-to-be-announced name.

United Technologies, an American multinational conglomerate, recently agreed to combine its aerospace business with military contractor Raytheon, creating a new manufacturing giant in the aerospace and defense sectors. Under the new name of Raytheon Technologies, the merged company would have about $74 billion in expected sales for 2019. 

In 2013, the USPTO enacted the After Final Consideration Pilot (AFCP) 2.0 program as an alternative response to a final rejection. The goal of the program was to increase communication between examiners and applicants and take those applications that are close to allowance across the finish line, without requiring the time and cost inevitably associated with an RCE.

Sprint and T-Mobile recently announced that they had reached a deal to merge, promising to “be a force for positive change in the U.S. wireless, video, and broadband industries.” Combining the country’s third and fourth largest mobile service providers would be one of the most significant consolidations in the American wireless market in years.

Thanks to Juristat patent analytics, practitioners can now leverage data to make strategic decisions throughout the patent prosecution process.

Watch our latest video to learn how firms and in-house teams can shape strategy with big data during all parts of the prosecution process.

Due to inconsistent interpretation, preparing for and responding to Alice rejections has become one of the most stressful aspects of patent prosecution. Rejections citing Alice have multiplied exponentially since the initial decision on June 19, 2014, and they now account for more than 60% of §101 rejections and more than 8% of all rejections, as of our latest analysis.

Two of the biggest pharmaceutical companies are joining forces in a blockbuster merger. Bristol-Myers Squibb is buying Celgene in a cash and stock deal valued at about $74 billion.